Pulmonary drug delivery systems are used to deliver the drug
to the lung for the treatment of respiratory diseases. Nebulizers, dry powder
inhalers (DPIs), and pressurized metered-dose inhalers (MDIs) are used in
pulmonary drug delivery. Pulmonary drug delivery systems are also used for the
treatment of migraine, lung cancer, and diabetes. The pulmonary route is used
to take the drug through the respiratory tract. The drug reaches the
bloodstream through the alveolar surface of the lungs.
It is widely used to treat cystic fibrosis, asthma, and
chronic obstructive pulmonary disease (COPD). It is a non-invasive technique. This
route is largely preferred due to high permeability rate, high blood
circulation, and large surface area for absorption, making this technique an
ideal method for the treatment of respiratory diseases. Pulmonary
drug delivery systems are in huge demand due to the increasing prevalence
of chronic diseases around the world. Chronic diseases such as diabetes,
cancer, and heart disease are the leading causes of death and disability in the
U. S.
According to the Centers for Disease Control and Prevention
(CDC), six in ten adults in the U.S. have a chronic disease and four in ten
have two or more chronic diseases. Compared to conventional drug delivery
systems, pulmonary drug delivery systems are ideal drug delivery systems due to
many advantages such as high vascularization, high drug loading efficiency, and
huge surface area present in alveolar sacs, which makes the lung an appropriate
site for drug absorption.
The significant increase in the target patient pool is
expected to increase the demand for pulmonary drug delivery systems. Pulmonary
systems were recently introduced into the pharmaceutical industry for the
treatment of both local and systemic lung diseases. Pulmonary drug delivery
systems are known to deliver the drug to the required site in the body through
the bloodstream.
Comments
Post a Comment